4 completed, 4 recruiting, 1 terminated. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Recruiting 4, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow fezolinetant: new trials by email Literature Review of fezolinetant trials Research Report on fezolinetant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) Fezolinetant, Placebo - Vasomotor Symptoms, Prostate Cancer | Phase 2 | Recruiting | Chinese University of Hong Kong | 54 | 2026-10-05 | 2026-10-07 |
| Focusing on the Menopausal Transition to Improve Mid-Life Women's Health Metformin, semaglutide, Anti-hypertensives - Menopause, Menopause Hot Flashes | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 200 | 2026-03-01 | 2026-11-04 |
| Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer Fezolinetant - Prostate CA, Androgen Deprivation Therapy | Phase 2 | Recruiting | University of Vermont | 32 | 2025-12-18 | 2026-02-05 |
| FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy Fezolinetant, Placebo - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Recruiting | Yale University | 92 | 2025-12-05 | 2026-11-03 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause Fezolinetant, Placebo - Hot Flashes | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 150 | 2025-03-10 | 2026-03-19 |
| Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial Biospecimen Collection, Fezolinetant, Placebo Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 9 | 2024-10-31 | 2026-05-06 |
| A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause Fezolinetant, Placebo - Hot Flashes | Phase 2 | Completed | Astellas Pharma Inc | 147 | 2021-11-17 | 2024-10-26 |
| A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes) Fezolinetant, Placebo - Menopause, Hot Flashes | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 356 | 2017-07-19 | 2024-11-26 |
| Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes Fezolinetant, Placebo - Hot Flashes | Phase 2 | Completed | Ogeda S.A. | 87 | 2015-09-21 | 2024-11-27 |
Hot Flashes (5) · Prostatic Neoplasms (2) · Carcinoma, Intraductal, Noninfiltrating (1)
Astellas Pharma Global Development, Inc. (2) · Astellas Pharma Inc (1) · Chinese University of Hong Kong (1) · Ogeda S.A. (1) · University of Colorado, Denver (1) · University of Michigan Rogel Cancer Center (1) · University of Vermont (1) · Yale University (1)
United States (5) · Belgium (1) · China (1) · Hong Kong (1) · Japan (1)
Chi Fai NG, MD (1) · Maryam Lustberg, MD (1) · Nanette Santoro, MD (1) · Norah L Henry (1)
2015 (1)